By: Dr. Alan N. Glazier OD, FAAO, Dipl. ABO
The pace of change in ophthalmic diagnostic equipment has accelerated dramatically over the past five years. What was once confined to academic medical centers or large group practices, swept-source OCT, AI-driven image analysis, cloud-based normative databases, is now accessible at virtually every level of clinical practice. For doctors of optometry and ophthalmology alike, this presents both an exciting opportunity and a real challenge: how do you evaluate, choose, and integrate these technologies in ways that genuinely improve patient outcomes and support a sustainable practice?
I’ve bought some amazing technology for my practice in the past, and I’ve also bought what I call “coat hangers”, tech I thought would drive a lot of value to the patients and the practice, but ended up stagnant, in a corner gathering dust and articles of clothing because we couldn’t fit into our clinical care regiment for one reason or another. This guide explains key advances, clarifies their benefits for you and your patients, and offers a framework for informed purchasing decisions as well as keep you from buying the most expensive “coat hanger” you’ve ever bought.
Enhanced Visualization: Seeing What Was Always There
Perhaps no area has evolved more rapidly than structural imaging of the eye. Optical coherence tomography (OCT) has long been a standard of care, but the jump to swept-source OCT and widefield imaging over the past several years represents a genuine qualitative leap, not just incremental improvement.
Swept-source platforms use longer wavelengths that penetrate deeper into the choroid and through media opacities such as cataracts or vitreous degeneration that previously degraded image quality. The clinical payoff is significant: you can visualize choroidal thickness and morphology with a clarity that changes how you interpret conditions such as central serous chorioretinopathy, myopic macular degeneration, and several others. Widefield capabilities now allow a single capture to image out to 200 degrees of retina, dramatically reducing the chance of missing peripheral pathology that would have required indirect ophthalmoscopy to detect.
OCT angiography (OCTA) has matured from a research novelty into a practical clinical tool. By mapping blood flow without dye injection, OCTA lets you assess the superficial and deep capillary plexuses, the choriocapillaris, and the foveal avascular zone in seconds. For diabetic retinopathy staging, early neovascularization detection, and macular disease monitoring, this is now a legitimate complement, and in many cases an alternative, to fluorescein angiography in the primary care setting.
AI and Normative Databases: Pattern Recognition at Scale
Modern diagnostic instruments are not just imaging devices, they are increasingly intelligent systems. The integration of AI-driven analysis with large normative databases is where much of the near-future value will be concentrated.
Current OCT and visual field platforms already employ machine learning to compare individual patient scans against databases of tens and hundreds of thousands of age-matched normal eyes. This allows the software to flag statistically significant deviations from expected structural norms before they are detectable by visual inspection alone. For glaucoma management in particular, this kind of trend-based, database-driven analysis is changing the threshold at which clinicians act — catching progression earlier and with greater confidence.
Looking ahead, AI will extend well beyond flagging abnormalities. Algorithms are being trained to predict disease progression, not just detect current status. Early research has demonstrated AI models that can predict, from a single retinal image, a patient’s likelihood of developing diabetic macular edema, glaucoma progression, or even systemic conditions such as cardiovascular disease. For the practicing clinician, this means your imaging equipment is evolving from a documentation tool into a prospective risk stratification engine. The organization advancing these technologies, the Alliance for Healthcare from the Eye, has partnered with eye care corporations including Topcon, academic institutions, associations such as the American Optometric Associations and technology companies like Microsoft, investing to develop these technologies, advancing them and raising public awareness that in this new world of AI-powered technology that ECPs are crucial 1st line providers of preventative whole health care.
Importantly, these systems are becoming better at explaining their reasoning. Explainable AI (XAI) outputs, which highlight the specific image features that drove a given result, help clinicians understand and trust the recommendation rather than simply accept a black-box output. This transparency is essential for clinical adoption and for patient communication.
Portability and Miniaturization: The Practice is Moving
A quiet but consequential shift has been the miniaturization of technologies that previously required a dedicated, immovable cost-prohibitive machines with significant space footprints. Handheld OCT devices, portable fundus cameras with smartphone integration, and tabletop anterior segment imagers have made it practical to bring high-quality diagnostic capability to satellite offices, nursing home visits, and hospital consults.
For multi-location practices, this represents a meaningful operational advantage: diagnostic continuity across all sites without duplicating full instrument suites at each location, eliminating the bottleneck of pretesting areas with expensive large machines so that it can be done in each exam lane, increasing practice efficiency. For practitioners with a significant low-vision, pediatric, or underserved population, the ability to image patients who cannot be positioned at a traditional instrument is a true paradigm shift in their ability to improve the practice of their specialty.
Headset Technologies: Reinventing Visual Field Testing
Visual field testing has historically been one of the most patient-unfriendly procedures in eye care, time consuming, exhausting for patients, with results that might be affected by patient cooperation issues and positioning variability, not to mention a dedicated dark-room with a large practice footprint. Virtual reality headset-based perimetry directly addresses this.
Platforms such as Heru, Olleyes VisuALL and similar VR-based systems administer threshold visual field testing in a wearable format that patients find more comfortable and engaging than the traditional bowl perimeter. Early validation studies show comparable sensitivity and specificity to Humphrey field analysis, the accepted standard for glaucoma detection and progression monitoring. Beyond comfort, these systems capture gaze-tracking data that enable real-time fixation monitoring and reliability scoring that go beyond the simple fixation-loss metrics of traditional perimetry.
Certain headset technologies also offer pretesting and screening capabilities beyond visual fields such as visual acuity testing, contrast sensitivity, color vision, and even binocular function assessment, consolidating multiple measurements into a single, portable, patient-friendly platform.
A Framework for Purchasing Decisions
Understanding the technology is one thing; choosing the right device for your practice is another. Here are the questions that should guide your evaluation:
1. Define clinical priority: Understand and identify the conditions you want to diagnose earlier or manage more precisely. A glaucoma-heavy practice has different needs than one focused on diabetic eye disease or pediatric care. Match the platform’s validated strengths to your actual patient population.
2. What does the workflow look like? A technically superior device that requires 15 minutes of setup or a highly trained technician to operate is not a practical improvement. Evaluate acquisition time, ease of use, and how naturally the output integrates into your electronic health record.
3. What normative data does the software use and is it relevant? Ask vendors about the composition of the normative database: sample size, age distribution, and ethnic diversity. An algorithm trained predominantly on one demographic may underperform for yours.
4. How is AI analysis validated? Request peer-reviewed evidence before you purchase, not just claims on how effective, efficient or clinical valid results the device provides. Understand sensitivity and specificity figures, what population was studied, and whether the AI recommendation is FDA-cleared for clinical use.
5. What is the total cost of ownership? Purchase price is only the beginning. Factor in service contracts, software update fees, consumable costs, and the revenue potential from new billable codes the device enables.
6. What are you allowing in terms of data when you sign a new contract? Don’t forget to ensure you read the contract thoroughly to understand (1) who owns the patient data (2) what the vendor is allowed to do with the data you collect (3) HIPAA concerns and who is legally responsible for violations if you are co-owners of the data (4) if the AI solution is FDA “cleared” and (5) the specific and direct definition of “warranty” in terms of performance and what it means. I’ll be covering these and other data concerns in a follow-up blog.
7. What does the upgrade path look like? The best platforms today will receive meaningful software updates, including AI enhancements. over their useful life. Choose manufacturers with a demonstrated commitment to ongoing development, not just the hardware sale.
The Bottom Line
The diagnostic instruments available to clinicians today are not simply better versions of what existed a decade ago, they represent a fundamentally different relationship between the clinician, the data, and the patient. AI will continue to shift the role of the practitioner from data collector to data interpreter, supporting faster, more confident, and more consistent diagnosis across a wider range of conditions.
The practices that will benefit most from these technologies are those that approach adoption thoughtfully: matching the tool to the clinical need, ensuring the team is trained to use it confidently, and understanding what the data means for each individual patient sitting in the chair. Technology amplifies good clinical judgment — it does not replace it. Approached that way, these advances represent one of the most meaningful expansions of scope and quality of care in the history of eye care.
